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A B S T R A C T
Finding excipients which mitigate protein self-association and aggregation is an important task during
formulation. Here, the effect of an equimolar mixture of L-Arg and L-Glu (ArgGlu) on colloidal and
conformational stability of four monoclonal antibodies (mAb1–mAb4) at different pH is explored, with
the temperatures of the on-set of aggregation (Tagg) and unfolding (Tm1) measured by static light
scattering and intrinsic ﬂuorescence, respectively. ArgGlu increased the Tagg of all four mAbs in
concentration-dependent manner, especially as pH increased to neutral. ArgGlu also increased Tm1 of the
least thermally stable mAb3, but without similar direct effect on the Tm1 of other mAbs. Raising pH itself
from 5 to 7 increased Tm1 for all four mAbs. Selected mAb formulations were assessed under accelerated
stability conditions for the monomer fraction remaining in solution after storage. The aggregation of
mAb3 was suppressed to a greater extent by ArgGlu than by ArgHCl. Furthermore, ArgGlu suppressed
the aggregation of mAb1 at neutral pH such that the fraction monomer was near to that at the more
typical formulation pH of 5.5. We conclude that ArgGlu can suppress mAb aggregation with increasing
temperature/pH and, importantly, under accelerated stability conditions at weakly acidic to neutral pH.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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Monoclonal antibodies (mAbs) are promising therapeutic drugs
for the treatment of a wide range of diseases (Chan and Carter,
2010; Leavy, 2010; Smith and Clatworthy, 2010; Weiner et al.,
2010). Their success is due to various properties including their
high binding speciﬁcity and afﬁnity, robust manufacturing
processes, and the availability of humanized forms that attenuate
immunogenic responses (Beck et al., 2010). However, mAb self-
association and aggregation is sometimes observed during
formulation at high concentrations (>100 mg/ml), and also with
environmental stresses such as shaking, changes in solution pH,
freeze–thaw and elevated temperatures (Banga, 2006; Chaudhuri
et al., 2014; Cromwell et al., 2006; Wu et al., 2014). Hence,
optimization of a mAb formulation by controlling buffer, ionic
strength and pH as well as the addition of excipients is crucial in* Corresponding author at: Manchester Institute of Biotechnology and Faculty of
Life Sciences, The University of Manchester, 131 Princess Street, Manchester
M1 7DN, UK. Tel.: +44 161 306 5813; fax: +44 161 306 5201.
E-mail address: A.Golovanov@manchester.ac.uk (A.P. Golovanov).
http://dx.doi.org/10.1016/j.ijpharm.2014.06.053
0378-5173/ã 2014 The Authors. Published by Elsevier B.V. This is an open access articminimizing the extent of aggregation (Aboel Dahab and El-Hag,
2014; Goldberg et al., 2011; He et al., 2011; Saito et al., 2013; Sule
et al., 2012).
All globular proteins, including mAbs are known to be
susceptible to aggregate formation. The term ‘protein aggregation’
can be deﬁned in a broad sense as any pathway forming protein
assemblies, or aggregates (Mahler et al., 2009). Aggregation may
result from the reversible self-association of the native protein, or
irreversible formation of non-native assemblies following the
partial or complete unfolding. (Aggregation through changes in
post-translational modiﬁcation and chemical degradation will not
be considered here.) Self-association involving native protein–
protein interaction may occur through complementary surface
effects, attractive electrostatic or short range attractive forces (He
et al., 2011; Liu et al., 2005). Such intermolecular self-association
of proteins is related to the colloidal stability, which can be
assessed by, for example, measuring temperature at which light
becomes scattered by protein aggregates appearing. Aggregation
involving partially unfolded protein may occur via exposed
hydrophobic patches, generating non-native assemblies, and is
related to the conformational stability of a protein (Arzenšek et al.,
2012; Goldberg et al., 2011; Pace et al., 1996; Shi et al., 2013).le under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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temperature of protein melting transition. Ideally, increasing both
the colloidal and conformational stability would be beneﬁcial for
creating a stable formulation, however in practice optimizing one
of these parameters may compromise the other.
When considering approaches to choosing mAbs formulation
for the best stability, the correct selection of buffer, pH and
excipient(s) is essential. The solution pH can have profound effects
on protein structure, stability and biological activity (Kopec and
Schneider, 2011; Thakkar et al., 2012). In the context of
formulation, pH is optimized to minimize physical and chemical
degradation pathways (Cromwell et al., 2006; Gokarn et al., 2008).
Generally, mAbs with a pI around 8–9 are formulated in mildly
acidic buffer, avoiding for example deamidation and aggregation
sometimes occurring in mildly alkaline buffer. These conditions
however are not necessarily the best for the optimal conforma-
tional stability. Another difﬁculty arises from the limited choice of
excipients available for formulation of pharmaceutical mAbs: only
those listed as Generally Recognized as Safe (GRAS) by the
regulatory bodies are used in practice (Ogaji et al., 2011; Pifferi and
Restani, 2003). Presently, the process of formulation (i.e. choosing
the best solution conditions and excipients) takes into account the
protein's physiochemical properties and may also involve high-
throughput screening (Li et al., 2011). Although there is no
‘universal excipient’ able to stabilize all the proteins, discovering a
combination of excipients which would be applicable for a wider
range of proteins is highly desirable.
An equimolar combination of the free amino acids L-arginine
and L-glutamic acid (ArgGlu) has been previously suggested
(Golovanov et al., 2004) as a way to increase the solubility limit and
long-term stability of several diverse proteins prone to aggrega-
tion; since then the method has been widely adopted in protein
structural and functional studies (Blobel et al., 2007, 2011;
Hautbergue and Golovanov, 2008; Valente et al., 2005; Vedadi
et al., 2006). L-Arginine itself (normally used in a form of a
hydrochloride salt, ArgHCl, to bring its solution pH down to
neutral) is a widely known additive which often is used to assist
protein refolding and reduce aggregation and solution viscosity
(Arakawa et al., 2007; Chen et al., 2008; Das et al., 2007; Fukuda
et al., 2014; Liu et al., 2005; Schneider et al., 2011; Vagenende et al.,
2013). However a number of studies established that on a per-mole
basis, ArgGlu is much more effective at reducing intermolecular
attractions and aggregation than L-Arg (Golovanov et al., 2004;
Valente et al., 2005; Vedadi et al., 2006). The mechanism of ArgGlu
effect has been investigated using experimental (Blobel et al., 2011)
and in silico methods (Shukla and Trout, 2011), which explained
the synergy of the action of L-Arg combination with L-Glu. The
signiﬁcant effect of ArgGlu on preventing protein aggregation is
observed already at 50 mM (Golovanov et al., 2004), with an in
silico study suggesting that an “optimum” concentration for an
anti-aggregation effect may exist in the range of 100–200 mM, at
least for the protein used for the simulations (Shukla and Trout,
2011). Recently, the stabilizing effect of high concentrations (up to
0.5 M) of ArgGlu versus ArgHCl on a selected IgG1 has been
explored which suggested that having L-Glu (or L-Asp) as counter-
ions counteracts the potentially disadvantageous destabilizing
effects of L-Arg (Fukuda et al., 2014). Despite the growing
popularity of using ArgGlu as excipients for increasing protein
solubility and preventing protein aggregation, to our knowledge,
the systematic studies of their utility for diverse mAbs in the
context of formulation as pharmaceuticals has not yet been
reported.
Here we used high-throughput analysis to screen the aggrega-
tion propensity and thermal stability of mAbs in a variety of
conditions. We ﬁrst investigated the concentration- and pH-
dependent effect of ArgGlu (in the pharmaceutically-acceptableosmolality range) on the temperatures of the on-set of aggregation
(Tagg) and ﬁrst melting transition (Tm1) of four IgG1 mAbs as
assessed by static light scattering (SLS) and intrinsic ﬂuorescence,
respectively. The effect of buffer type and solution pH on the
stability of selected mAb formulations was then explored under
accelerated stability conditions (storage at elevated temperature
for a number of weeks), analysed for the fraction monomer by size
exclusion high pressure liquid chromatography (SE-HPLC). The
results suggest that using ArgGlu as excipient at concentrations
<200 mM can reduce temperature-induced aggregation of mAbs
especially at pH approaching neutral, where the inherent
conformational stability of mAbs is theoretically higher.
2. Materials and methods
2.1. Monoclonal antibodies and sample preparation
The four different mAbs (IgG1 with MWs from 145 to 148 kDa)
tested here were kindly provided by MedImmune. The isoelectric
points (pI) of mAb1, mAb2, mAb3 and mAb4 are 7.9–8.3, 8.44, 8.56
and 8.53, respectively; all values were measured experimentally
except for that of mAb2 which was calculated. For SLS and intrinsic
ﬂuorescence measurements, the mAbs were diluted to 1 mg/mL in
10 mM citrate–phosphate (C–P) buffer (pH 5–7). These solutions
were supplemented with varying concentrations of ArgGlu (50–
200 mM) as required, using prepared 1 M stock solution (Golova-
nov et al., 2004) containing equimolar mixture of the free amino
acids L-Arg (Analytical grade, Sigma–Aldrich) and L-Glu (USP-FCC
grade, J.T. Baker) in MilliQ water (18.2 MV cm), with pH adjusted
where necessary. For preparation of buffers containing ArgHCl,
the hydrochloride salt of L-Arg was used (USP-FCC grade, J.T. Baker).
The mAbs were diluted to 0.5 mg/mL for absorption measurements
at 280 nm. For SE-HPLC, mAbs were diluted to 10 mg/mL in the
appropriate buffer.
2.2. Determining solution osmolality
The osmolality of ArgGlu solutions in the presence and absence
of a mAb2 was measured using an Osmomat 030-D Cryoscopic
Osmometer (Gonotec GmbH, Berlin, Germany). Measurement
results are shown in Supplementary Information, Fig. S1. ArgGlu
concentrations of 5, 10, 25, 50, 100, 150 and 200 mM were prepared
from a 1 M stock in MilliQ water, and also at concentrations of 50,
150 and 200 mM in 10 mM C–P buffer, pH 6.0. For solutions
containing protein, mAb2 was buffer exchanged using overnight
dialysis into 10 mM C–P buffer, pH 6.0, containing ArgGlu
concentrations of 50, 150 and 200 mM. The protein concentration
was adjusted by dilution with the appropriate ArgGlu solution to
30 mg/ml; concentrations were veriﬁed in triplicate using a Nano-
Drop 2000 (Thermoscientiﬁc, Stafford House, Hertfordshire), by
measuring optical absorption at 280 nm.
2.3. Static light scattering and intrinsic ﬂuorescence
SLS and intrinsic ﬂuorescence measurements were conducted
simultaneously using an Optim 2 (Avacta, Thorp Arch Estate,
Wetherby). Data was processed using the standard Optim analysis
software provided (Avacta, 2013a), as per manufacturer's recom-
mendations (Avacta, 2013b). Brieﬂy, the SLS at 266 nm was used as
an indicator for “colloidal stability”, reporting the onset of
aggregation temperature (Tagg), which can be deﬁned as the
temperature at which the measured scatter reaches a threshold
that is approximately 10% of its maximum value (for typical trace,
see Supplementary Information, Fig. S2). The changes in the SLS
signal represented changes in the weight average molecular mass
observed due to protein aggregation. The conformational stability
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melting, namely the mid-point temperature of the ﬁrst unfolding
transition, Tm1 (see Supplementary Information, Fig. S3), moni-
tored by an intrinsic ﬂuorescence intensity ratio (350/330 nm)
which is sensitive to the tryptophan exposure as protein unfolds
(Avacta, 2013b). The samples were heated from 20 to 90 C using
1 C increments, with an equilibration time of 60 s before each
point measurement. The sample measurements were made in
triplicate and statistical analysis made using GraphPad Prism v6.
2.4. Controlled temperature storage stability studies
Accelerated stability studies were set up for mAb1, mAb3 and
mAb4 (there was insufﬁcient resource for mAb2) at concen-
trations between 30–50 mg/mL in 10 mM C–P buffer. Two
formulations were prepared for each mAb in order to compare
the stabilizing effect of ArgGlu versus ArgHCl and the effect of
pH. The formulated mAbs were transferred to glass vials and
stored for a number of weeks at controlled temperatures of 5, 25
and 40 C (40 C was considered to represent stress conditions).
The samples were tested every week by SE-HPLC, using a Tosoh
TSKgel column (with 5 mm beads) attached to Agilent HPLC 1200
system, monitored at 280 nm. Samples of 25 ml were injected
each time, with a running buffer of 100 mM sodium phosphate,
100 mM NaCl, pH 6.8, and monitoring the absorbance proﬁle at
280 nm. The peaks on the chromatograms were analysed to
determine the percentage of mAb monomer present in solution,
with each experiment carried out in duplicate.
3. Results
3.1. The effect of ArgGlu on mAb colloidal stability
The Tagg value, derived from the temperature dependence of the
SLS signal, was used as a measure to assess the colloidal stability of
four mAbs tested, as a function of solution pH (in the range 5–7) and
ArgGlu concentration (0–200 mM). This pH range included the
mildly acidic region (pH 5–6) commonly used for mAb formulation,Fig. 1. Change in Tagg as a function of pH for different concentrations of added ArgGlu 
independent experiments.and neutral pH which may sometimes be expected to promote mAb
aggregation, due to its proximity to pI. Previous experimental
studies have showed that whereas an addition of equimolar L-Arg
and L-Glu at concentrations as low as 50 mM increases the solubility
of proteins prone to aggregation in a concentration-dependent
manner (Golovanov et al., 2004), more recent theoretical in silico
studies suggested that L-Arg and L-Glu may reach a maximum effect
at 150 mM, at least for a model protein used in simulations (Shukla
and Trout, 2011). Therefore, the range of ArgGlu concentrations
chosen for the current study was extended up to 200 mM, which
encompassed typical osmolalities used in the formulation of
proteins for subcutaneous injection (Supporting Information,
Fig. S1). In a control experiment, no signiﬁcant light scattering
was observed for ArgGlu solutions in the absence of protein. The
light scattering in the presence of protein in subsequent experi-
ments therefore was directly attributed to protein aggregation
(Supporting Information, Fig. S2).
The intrinsic Tagg values (i.e. those observed at pH 5, which is
furthest away from the pI, and in the absence of ArgGlu) for the
four mAbs were quite diverse (ranging between ca. 54 and 83 C),
showing that the mAbs selected for these studies represent a wide
range of inherent colloidal stabilities (Fig. 1). In the absence of
ArgGlu all the mAbs showed a consistent downward trend in Tagg
values with increasing pH (Fig. 1). The addition of ArgGlu however
largely recovered the fall in Tagg in a concentration-dependent
manner, such that for a maximal concentration of ArgGlu at pH 7,
the Tagg was very close to that at pH 5, and for mAb1 it was actually
20 C higher (Fig. 1). At pH 5, the Tagg values for all mAbs except
mAb1 were insensitive to the ArgGlu concentration added. For
mAb1 at pH 5, Tagg systematically increased with increasing
ArgGlu concentrations, by up to 9 C. Moreover, increasing ArgGlu
concentrations increased Tagg for mAb1 (which had the lowest
inherent Tagg of all antibodies tested here) consistently over all pH
tested (Fig. 1). For all mAbs at pH > 5, the addition of ArgGlu
increased their colloidal stability, with this effect being more
noticeable at higher, neutral pH. It is interesting that at neutral pH
7 (see Fig. 2) the Tagg continued to increase as ArgGlu
concentration was increased for mAb1 and mAb2, whereas forfor the four mAbs as labelled. Error bars represent the standard deviation for three
Fig. 2. Change in Tagg of four mAbs at pH 7 as a function of ArgGlu concentrations, as labelled. Error bars represent the standard deviation for three independent experiments.
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100 mM ArgGlu and with the signiﬁcant stabilizing effect being
observed when adding just 50 mM ArgGlu (Fig. 2).
3.2. The effect of ArgGlu on mAb conformational stability
Conformational stability of mAbs was assessed here by the
melting temperature Tm1, measured from the temperatureFig. 3. Change in Tm1 as a function of pH for different concentrations of added ArgGlu fo
comparisons of thermal stabilities of different mAbs. Error bars represent the standarddependence of intrinsic ﬂuorescence signal (a typical trace is
shown in Supplementary Information, Fig. S3). In a control
experiment, no ﬂuorescent signal was detected in the absence
of protein, for all ArgGlu concentrations tested in C–P buffer at the
different pH (data not shown), conﬁrming that the intrinsic
ﬂuorescence measured was related to the protein sample only. As
can be seen in Fig. 3, generally, an increase in solution pH caused
increase in Tm1 for most of the mAbs and most of the bufferr the four mAbs as labelled. All graphs have the same y-axis scale to enable relative
 deviation for three independent experiments.
Table 1
Formulation conditions chosen for comparative accelerated stability studies of the three selected mAbs.
Base buffer mAb1 mAb3 mAb4
10 mM citrate–phosphate + 200 mM ArgGlu 10 mM citrate–phosphate, pH 5.5 10 mM citrate–phosphate, pH 5.5
Formulation 1 pH 5.5 +200 mM ArgGlu +200 mM ArgGlu
Formulation 2 pH 7.0 +200 mM ArgHCl +200 mM ArgHCl
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the buffer without ArgGlu for the mAb3. Notably, for mAb1, mAb2
and mAb4, Tm1 values were between 60 and 65 C at pH 5 and rose
towards 70 C at pH 7, while Tm1 values for mAb3 at pH 5 were
46 C and rose towards 50 C at pH 7 in the presence of ArgGlu.
The mAb3 is appreciably less conformationally stable compared to
the other mAbs tested under these buffer conditions.
For all mAbs the general increase in Tm1 with pH was relatively
little inﬂuenced by the addition of ArgGlu. However, for the least
stable of the four antibodies, mAb3, a stabilizing effect of ArgGlu
was observed, especially at pH 7 where the difference in Tm1 for 0
and 200 mM ArgGlu was 5 C (Fig. 3). No clear trend in Tm1 versus
ArgGlu concentration was observed for mAb2, and for mAb1 and
mAb4 a possible marginal destabilization at a given pH could be
inferred (although this effect was only observed at pH 7 for mAb1
and was rather insigniﬁcant for mAb4, Fig. 3). Thus, the Tm1 results
indicated that ArgGlu in the concentrations up to 200 mM used
here, had a relatively small and variable, mAbs-dependent effect on
conformational stability. However, most importantly, although the
direct effect of ArgGlu on the melting temperature Tm1 was
relatively small, the effect of raising the pH towards neutral had a
more signiﬁcant and consistent effect, raising the Tm1 of all mAbs
tested here. The conformational stability which can be achieved in
the presence or absence of ArgGlu as reﬂected by Tm1, was always
higher at pH 7 than at pH 5.
3.3. Controlled temperature storage stability studies
To investigate how the presence of ArgGlu affected the overall
long-term stability of mAbs formulated at higher concentrations,
several test conditions (pH and additives) and three mAbs which
show a characteristic behaviour were selected. We ﬁrst explored
the observed insensitivity of Tagg of mAb1 to pH in the presence of
high concentration of ArgGlu by formulating at pH 5.5 and 7.0, and
second, compared the effect of adding ArgHCl versus ArgGlu onFig. 4. Monomer loss determined from SE-HPLC data for mAb1 stored over 6 weeks
at 5, 25 and 40 C in 10 mM CP buffer, 200 mM ArgGlu pH 5.5 or 7, as labelled. The
percent monomer at time = 0 for both formulations was 99.0%. Data reported were
derived from two independent measurements which differed by <5%.mAb3 (which is the least conformationally-stable) and mAb4
(which is comparatively stable). The resultant formulations are
summarized in Table 1.
The solutions of chosen mAbs were prepared at 30–50 mg/ml
concentration and taken forward to check the long-term stability
of these samples after storage at different temperatures. The
percentage of monomeric protein remaining in solution was
monitored over time to assess the effect of condition parameters,
in a comparative fashion. The colloidal stability of mAb1 in the
absence of ArgGlu was clearly better at low pH (Fig. 1):
interestingly, in the accelerated stability study in the presence
of ArgGlu the difference in loss of monomer at pH 7.0 versus pH 5.5
was a relatively small value of <2% after storage at 40 C for 6
weeks (Fig. 4). The higher inherent aggregation propensity at pH
7.0 for mAb1 can be explained by it being closer to its pI, measured
to be in the region 7.9–8.3 (data not shown), which is the lowest pI
of the four mAbs tested. In the absence of ArgGlu the Tagg at this pH
is only 43 C (see Fig.1) which is close to the storage temperature of
40 C used in this experiment. It is rather remarkable then, that in
the presence of 200 mM ArgGlu mAb1 remains appreciably stable
for weeks at 40 C at pH 7, with more than 93% of monomeric form
still remaining in solution after six weeks.
The mAb3 was the least conformationally stable antibody, with
the lowest Tm1 (Fig. 3). For mAb3, the performance of ArgGlu
versus ArgHCl as an enhancer of the long-term stability was
compared at pH 5.5 (see Table 1). Under accelerated conditions at
40 C, it became possible to discern a clear preference for ArgGlu
over ArgHCl over all time points tested (Fig. 5). Already after one
week at 40 C, there was a dramatic decline of almost 30% in the
monomer population in the presence of ArgHCl, which is halved in
the presence of ArgGlu (15% monomer loss). Similarly to what
was observed for mAb1, there were only small (<5%) differences in
mAb3 stability when stored at 5 or 25 C. Much longer storage
times, up to several months, would probably be required to
distinguish between the two arginine salts at these lowerFig. 5. Monomer loss determined from SE-HPLC data for mAb3 stored over 8 weeks
at 5, 25 and 40 C in 10 mM CP buffer pH 5.5, with addition of arginine salts ArgGlu
or ArgHCl, as labelled. The percent monomer at time = 0 for both formulations was
99.1%. Data reported were derived from two independent measurements which
differed by <5%.
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from its intrinsic Tm1 (45 C, see Fig. 3) which would explain the
relatively fast decrease in the monomer population observed for
this mAb3 when stored at this higher temperature. Overall, for
mAb3 ArgGlu provided a better storage stabilization than ArgHCl.
As a combination of pH 7 with 200 mM ArgGlu increases Tm1 for
mAb3 by about 5 C (see Fig. 3) without signiﬁcantly compromising
Tagg (Fig. 1), it will be interesting to check in the future if using pH 7
would afford a better overall storage stability of this antibody at
high temperature.
The third antibody tested, mAb4, has relatively high values of
both Tagg and Tm1 (see Figs. 1 and 3), and hence is a comparatively
stable antibody. Here, we compared the relative performance of
ArgGlu versus ArgHCl. Despite extending storage for up to 10
weeks, no obvious difference in monomer loss was observed for
addition of 200 mM ArgGlu or ArgHCl, at all temperatures (5, 25
and 40 C) (Fig. 6). Similarly to observations for mAb1 and mAb3,
there was less than 1% loss of monomer over the study period at 5
or 25 C, while larger losses were recorded at 40 C; although in the
case of mAb4 these losses were small at 4% over 6 weeks. For
mAb4 formulated at pH 5.5, we have not found signiﬁcant
difference between performance of ArgGlu versus ArgHCl (Fig. 6).
Interestingly however, the mAb1, which is inherently prone to
aggregation, when formulated in 200 mM ArgGlu showed a
monomer decay pattern (Fig. 4) very similar to that of a ‘stable’
mAb4 (Fig. 6), suggesting that usage of ArgGlu in formulations can
be beneﬁcial, especially for mAbs which are less stable and more
prone to aggregation. Although for mAb4, which was stable under
the stress conditions tested in this study, no immediate further
beneﬁt of using ArgGlu versus ArgHCl was observed, it still
remains to be explored if this excipient can have beneﬁcial effect
on stability under more extreme stress conditions, when even the
most stable mAbs start to degrade, e.g. during long-term room-
temperature storage.
4. Discussion
The main purpose of this study was to examine the concentra-
tion-dependent effect of ArgGlu on the physical stability of
representative mAbs at different pH. Either (or both) colloidal andFig. 6. Monomer loss determined from SE-HPLC data for mAb4 stored over 10
weeks at 5, 25 and 40 C in 10 mM CP buffer pH 5.5, with addition of arginine salts
ArgGlu or ArgHCl, as labelled. The percent monomer at time = 0 for both
formulations was 98.9%. Data reported were derived from two independent
measurements which differed by <5%. Only data from week 3 onwards is shown on
the graph as there was no signiﬁcant change in the percent monomer before that
(data for weeks 1 and 2 are very similar to week 3).conformational stability can control the rate and extent of
aggregation, which is one of the main degradation pathways for
therapeutic mAbs (Goldberg et al., 2011). The colloidal stability, or
the ability of solution conditions to reduce self-association and
aggregation of mAbs can be conveniently assessed by recording the
temperature, Tagg, at which SLS signal, which is sensitive to
formation of aggregates in solution, starts to increase (Avacta,
2013b; Goldberg et al., 2011). The conformational stability, or the
ability of protein to maintain its native folded state, can be assessed
in different formulation conditions by looking at the temperature
of the ﬁrst unfolding transition, Tm1, measured using temperature
dependence of intrinsic ﬂuorescence signal (Avacta, 2013b;
Goldberg et al., 2011). These methods require only small amounts
of samples and allow quick and high-throughput assessment of
whether protein is stabilized or destabilized under particular
solution conditions (Avacta, 2013b; Goldberg et al., 2011).
Initial investigation of the colloidal stability of the four mAbs in
the pH range 5–7 revealed a general drop in the Tagg as pH came
closer to pI, however this drop was largely recovered upon the
addition of ArgGlu. In the case of mAb3 and mAb4, 50 mM ArgGlu
was sufﬁcient to bring about a near-complete recovery of the Tagg,
corroborating earlier ﬁndings showing the same concentration
signiﬁcantly increased protein solubility (Golovanov et al., 2004).
For the same mAbs increasing ArgGlu concentrations above
100 mM yielded almost no further increase in Tagg, suggesting that
an optimal concentration of these additives may indeed exist,
which is in agreement with theoretical simulations (Shukla and
Trout, 2011). Such concentration may be in the range of
osmolalities which are pharmaceutically-acceptable for the anti-
body formulations intended for injections. In the case of mAb1 and
mAb2, the ArgGlu concentration-dependent increase in Tagg did
not reach saturation at pH 6–7, therefore the optimal concentration
of ArgGlu may be different for different mAbs and concentrations
above 200 mM may be beneﬁcial in some cases for a greater
stabilization against aggregation. Interestingly, for the majority of
mAbs tested here, the recovery in Tagg by ArgGlu appeared to be
limited to a Tagg value observed at pH 5, i.e. for mAb1 and mAb2 it is
likely that a saturable limit also exists above 200 mM ArgGlu.
Generally, at pH 5, the effect of addition of ArgGlu on Tagg was
signiﬁcant only for the most aggregation-prone antibody, mAb1,
which had the lowest Tagg. This addition increased the value of Tagg
by up to 9 C, to the typical level observed for other, more stable
antibodies (Fig. 1). However, the Tagg values of antibodies which
were already stable against aggregation at this pH were not affected.
The likely explanation for this is that the colloidal stability of these
proteins is already enforced by the electrostatic repulsion of the
positively-charged protein molecules, as pH is far away from the pI.
Consideration of conformational stability is important in
formulation since occurrences of partial protein unfolding may lead
to the exposure of hydrophobic ‘sticky’ patches and subsequent
aggregation. Ideally, conformational stability should be maximized.
The intrinsic ﬂuorescence data during thermal denaturation for all
the mAbs shows a general increase inTm1as pH increased from 5 to 7.
In comparison with this general trend, the addition of ArgGlu had
relatively small and variable direct effect on the Tm1 of the mAbs
studied, although mAb3, the least conformationally-stable anti-
body, presented an interesting case since its conformational
stability increased with ArgGlu addition in a concentration-
dependent manner. A molecular mechanism for this effect may
relate to the ion-speciﬁc effects of ArgGlu via the guanidinium
group, which is chaotropic in nature within the Hofmeister series.
Collins (1997) proposed that chaotropic ions speciﬁcally bind like-
charged chaotropic residues (i.e. arginine, lysine) on the protein
surface (and vice versa for kosmotropes) (Collins, 1997). Further
experiments would be required, comparing the effects of ArgGlu
and ArgHCl on mAb3, especiallyat pH 7, to clarify the mechanism of
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stability perspective, there appears to be a clear advantage in using
pH closer to 7 for all four mAbs tested here.
Given that the addition of ArgGlu at pH 6–7 enables to largely
recover the Tagg back to the values typically observed at pH 5, it may
be interesting to exploit this effect in the context of hypothetical
formulations for mildly basic proteins at a pH around neutral.
Generally, protein therapeutics are formulated so that the pH of the
formulation is at least 1 unit away from the pI of the molecule
(Lehermayr et al., 2011). In theory however, when the solution pH
is equal to the protein's pI the electrostatic contributions to
conformational stability should be maximal (Ugwu and Apte,
2004). Our observations for Tm1 dependence on pH (Fig. 3) fully
support this prediction experimentally. It follows that if ArgGlu
can indeed mitigate the loss of colloidal stability on moving
towards the pI of a mildly basic protein, there may exist the
possibility of increasing the formulation space towards higher pH
values, where protein is inherently more stable conformationally.
This possibility has been previously postulated in the context of
formulation in the biopharmaceutical industry (Banga, 2006).
The Tagg and Tm1 data demonstrate that, in the range of
concentrations giving rise to clinically-acceptable solution osmo-
lality, ArgGlu had a signiﬁcant, positive direct effect on the mAbs'
colloidal stability but a relatively small direct effect on their
conformational stability. These ﬁndings agree with previous
studies which showed that ArgGlu appears to attenuate protein
self-association and does not signiﬁcantly affect the conformation
of natively folded protein (Golovanov et al., 2004; Vedadi et al.,
2006). Using molecular dynamics, Shukla and Trout (2011)
proposed a molecular mechanism wherein hydrogen bonding
between Arg and Glu facilitates an increase in the concentration of
both ions at the protein surface, augmenting the crowding effect
and suppressing protein–protein interaction (Shukla and Trout,
2011). Interestingly, recently it was suggested that at high
concentrations (0.5 M) the presence of L-Glu or L-Asp as counter-
ions for L-Arg may mitigate some of the destabilizing effects of L-
Arg alone (Fukuda et al., 2014).
In addition to investigating the effect of ArgGlu on Tagg and Tm1
individually when mAbs are at low concentrations, it is important
to check whether any perceived improvements in these stability
parameters translate into improvements in the overall storage
stability in more concentrated form, especially at elevated
temperature. We selected a set of formulation conditions and
three antibodies showing characteristic inherent behaviour: one
with low Tagg (mAb1), one with low Tm1 (mAb3), and
one comparatively stable (mAb4). We explored the long-term
storage stability (i.e. the percentage of monomer still remaining in
the solution) of these antibodies in the presence of 200 mM
ArgGlu comparing it with a reference formulation. Although the
rate of aggregation at 40 C of mAb1 was slightly less (by <2%) at
pH 5.5 than at pH 7, the overall storage stabilization afforded by
ArgGlu at neutral pH for this protein at higher concentration is
itself remarkable. Indeed, in the absence of ArgGlu at pH 7 which
is approaching the pI, mAb1 even at low concentration is heavily
prone to aggregation at elevated temperature. The assessment of
colloidal and conformational stability of this mAb1 performed at
lower protein concentration (Fig. 1) has revealed that in the
presence of 200 mM ArgGlu this protein becomes colloidally-
stable over the whole range of pH. The long-time storage
experiment for mAb1 under thermal stress thus conﬁrmed that
the overall stability of this formulation at pH 7 indeed is very
similar to that at pH 5.5, which highlights the usefulness of
assessing Tagg and Tm1 as a way to predict the overall protein
stability in different conditions.
Another protein, mAb3, which had the lowest inherent Tm1, also
demonstrated an interesting behaviour: at pH 5.5 the suppressionof aggregation was signiﬁcantly greater for ArgGlu than for
ArgHCl. Despite the proximity of its inherent Tm1 value of 45 C to
the storage temperature, in the presence of 200 mM ArgGlu a
signiﬁcant proportion of this protein (52%) remained in solution as
monomer even after 8 weeks. Given that the inherent Tm1 of mAb3
at pH 7 and in the presence of ArgGlu is expected to be higher than
at pH 5.5 used in this experiment (see Fig. 3), it would be
interesting in the future to assess its long-term storage stability
under thermal stress at pH 7, and compare that with the
performance of another L-Arg salt, ArgHCl. The beneﬁt of using
ArgGlu versus ArgHCl was not however evident for the most
stable mAb4: more challenging stress conditions may be needed
for such discrimination in this case. Overall, these data support our
proposal (based on Tagg and Tm1 data) that the use of ArgGlu may
facilitate the formulation of mildly basic proteins at neutral pH.
The relative advantages of using ArgGlu as opposed to ArgHCl
(albeit, at much higher concentrations of these amino acids than
used in the current study) were also recently highlighted by
Fukuda et al. (2014), suggesting that the presence of L-Glu or L-Asp
as a counter-ion for L-Arg mitigate some of the destabilizing
properties of arginine alone (Fukuda et al., 2014).
5. Conclusions
ArgGlu has the potential to increase the physical stability of
mAbs formulated at weakly acidic to neutral pH. Depending on the
particular mAb, stabilization as measured by Tagg scales with
increasing concentrations of ArgGlu to at least 200 mM, or reaches
a plateau around 100 mM with even 50 mM affording signiﬁcant
beneﬁt. Thus, ArgGlu is effective at relatively modest concen-
trations (<200 mM) giving rise to osmolalities acceptable for
injections. The direct effect of ArgGlu at these concentrations on
the melting temperature Tm1 of the mAbs appeared marginal,
unlike the effect of pH itself, which signiﬁcantly increases Tm1 as
pH approaches 7. Under accelerated stability conditions, ArgGlu
reduced monomer loss for the least stable mAb to a greater extent
than observed for ArgHCl, and suppressed aggregation at pH 7.0 to
near that observed at pH 5.5. ArgGlu may therefore be a potential
alternative to ArgHCl in mAb formulation development, though
further studies will be required to better understand its
applicability at higher protein concentrations, by assessing a
wider range of formulation conditions.
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